ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01627054
Recruitment Status : Completed
First Posted : June 25, 2012
Last Update Posted : October 26, 2016
Sponsor:
Collaborator:
Astex Pharmaceuticals
Information provided by (Responsible Party):
Canadian Cancer Trials Group ( NCIC Clinical Trials Group )